C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
Φόρτωση...
Ημερομηνία
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Int J Cancer
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochemistry and confocal immunofluorescence. Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade. Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression. Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addition to Her2/neu. Median disease-free survival in patients with c-Met overexpressing tumors was 8 months compared to 53 months when c-Met expression was low (p = 0.037; RR = 3.0). This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate analysis. In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further analysis in a larger cohort of patients.
Περιγραφή
Λέξεις-κλειδιά
Adult, Aged, Aged, 80 and over, Breast Neoplasms/drug therapy/*metabolism/*pathology, Disease Progression, Disease-Free Survival, Female, Fibrocystic Breast Disease/drug therapy/metabolism/pathology, Hepatocyte Growth Factor/metabolism, Humans, Hyperplasia/drug therapy/metabolism/pathology, Ligands, Lymph Nodes/pathology, Lymphatic Metastasis/*pathology, Middle Aged, Neoplasm Staging, Pilot Projects, Proto-Oncogene Proteins c-met/*metabolism, Receptor, erbB-2/*metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone/metabolism, Risk Factors, Survival Rate, Treatment Outcome
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/15455388
http://onlinelibrary.wiley.com/store/10.1002/ijc.20598/asset/20598_ftp.pdf?v=1&t=h0dok7re&s=254db45fd575faa12905ce0be944e6cd20b0278f
http://onlinelibrary.wiley.com/store/10.1002/ijc.20598/asset/20598_ftp.pdf?v=1&t=h0dok7re&s=254db45fd575faa12905ce0be944e6cd20b0278f
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής